More about

Nivolumab

News
June 29, 2021
1 min read
Save

NSCLC treatment failure increases with genomic aberration, never-smokers, non-resection

Tyrosine kinase inhibitor-sensitive genomic aberrations, unresected tumors and not smoking were associated with increased treatment failure in non-small cell lung cancer, according to a presentation at the virtual ASCO annual meeting.

News
June 25, 2021
1 min read
Save

Checkmate9LA demonstrates benefit of combination therapy in advanced NSCLC

A 2-year update on Checkmate9LA suggested that combining nivolumab with ipilimumab and two cycles of chemoradiation may be better than four cycles of chemoradiation alone, according to a speaker at the virtual 2021 ASCO Annual Meeting.

News
June 09, 2021
3 min read
Save

Adding nivolumab to neoadjuvant chemotherapy does not impede surgery in resectable NSCLC

Adding nivolumab to neoadjuvant chemotherapy does not impede surgery in resectable NSCLC

The addition of nivolumab to neoadjuvant chemotherapy appeared safe and did not impact timing or feasibility of surgery among patients with resectable non-small cell lung cancer, according to results of the phase 3 CheckMate 816 trial.

News
June 08, 2021
4 min read
Save

‘Encouraging’ results with transurethral resection, systemic therapy for bladder cancer

‘Encouraging’ results with transurethral resection, systemic therapy for bladder cancer

Transurethral resection of bladder tumor plus systemic therapy induced clinical complete response among a large subset of patients with muscle-invasive bladder cancer, according to phase 2 study results.

News
June 03, 2021
2 min read
Save

Two nivolumab regimens outperform chemotherapy alone in advanced esophageal cancer

Two nivolumab regimens outperform chemotherapy alone in advanced esophageal cancer

The addition of nivolumab to chemotherapy or ipilimumab significantly improved OS compared with chemotherapy alone among patients with previously untreated advanced esophageal squamous cell carcinoma, according to phase 3 study findings.

News
May 20, 2021
2 min read
Save

FDA approves Opdivo for esophageal, gastroesophageal junction cancers

FDA approves Opdivo for esophageal, gastroesophageal junction cancers

The FDA approved nivolumab as adjuvant treatment for certain patients with completely resected esophageal or gastroesophageal junction cancers, according to the agent’s manufacturer.

News
May 20, 2021
4 min read
Save

Dual checkpoint blockade improves PFS as first-line treatment of advanced melanoma

Dual checkpoint blockade improves PFS as first-line treatment of advanced melanoma

The addition of relatlimab to nivolumab conferred a significant PFS benefit among treatment-naive patients with advanced melanoma, according to results of the phase 2/phase 3 RELATIVITY-047 study presented at the virtual ASCO Annual Meeting.

News
May 06, 2021
1 min read
Save

Top in hem/onc: Checkpoint inhibitor indications, loneliness of childhood cancer survivors

Top in hem/onc: Checkpoint inhibitor indications, loneliness of childhood cancer survivors

Last week, an FDA panel voted against maintaining a gastric cancer indication for pembrolizumab and a hepatocellular carcinoma indication for nivolumab. It was the top story in hematology/oncology.

News
April 30, 2021
1 min read
Save

FDA grants priority review to Opdivo as adjuvant treatment of urothelial carcinoma

FDA grants priority review to Opdivo as adjuvant treatment of urothelial carcinoma

The FDA granted priority review to nivolumab for adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma, according to the agent’s manufacturer.

News
April 20, 2021
3 min read
Save

Addition of nivolumab to neoadjuvant chemotherapy confers benefit in resectable NSCLC

Addition of nivolumab to neoadjuvant chemotherapy confers benefit in resectable NSCLC

The addition of nivolumab to neoadjuvant chemotherapy led to a significantly higher pathologic complete response rate among patients with resectable non-small cell lung cancer, according to results of a randomized phase 3 trial.

View more